2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 14:04, 15 September 2023
, 15 September 2023→Studies
| Line 104: | Line 104: | ||
|Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study <ref>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265078/</ref> | |Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study <ref>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265078/</ref> | ||
|[[RCT]], 6 weeks | |[[RCT]], 6 weeks | ||
* | * placebo (n=12) | ||
* | * 300 mg/day (n=12) | ||
* | * 600 mg/day (n=12) | ||
* | * 1200 mg/day (n=12) | ||
| | | | ||
* 48 young and middle-aged recreationally trained runners | * 48 young and middle-aged recreationally trained runners | ||